Back to search results
NCT04565665

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~65 participants
Updated 2026-05-20 on ClinicalTrials.gov
What's tested:Best PracticeMesenchymal Stem Cell

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of composite serious adverse events (Phase I)
Measured over Within 30 days of the first mesenchymal stem cell (MSC) infusion
+3 more outcomes measured

Conditions

COVID-19 Infection
COVID-19-Associated Acute Respiratory Distress Syndrome
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Symptomatic COVID-19 Infection Laboratory-Confirmed

Explore related trials

Acute Respiratory Distress SyndromeCOVID-19 InfectionHematologic NeoplasmSolid Neoplasm

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Amanda Olson · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Moribund participants not expected to survive up to 48 hours
Participants with severe chronic liver disease (Childs-Pugh score \> 10)
Pregnant and/or lactating women
Participants on extracorporeal membrane oxygenation

What this trial measures

  • Incidence of composite serious adverse events (Phase I)Within 30 days of the first mesenchymal stem cell (MSC) infusion

    Serious adverse events with be comprised of grade 3 or 4 graft versus host disease or death and will be estimated and reported overall and by group, along with 95% confidence intervals.

  • Patients alive without grade 3, 4 infusional toxicity (Phase II)At day 30 post MSC infusion
  • Patients alive with grade 3 or 4 infusional toxicity (Phase II)At day 30 post MSC infusion
  • Patients not alive (Phase II)At day 30 post MSC infusion